Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Victoria Glover et al.|The Lancet Respiratory Medicine|2021Cited by 434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy‐Mee Yu, Simon de Lusignan, Richard Hobbs et al.|The Lancet|2021Cited by 310
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysisJonathan Baker, Mona Bafadhel, Louise Donnelly et al.|The Lancet Respiratory Medicine|2022Cited by 58
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trialChristopher Butler, Simon de Lusignan, Richard Hobbs et al.|medRxiv|2021Cited by 28
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Victoria Glover et al.|medRxiv|2021Cited by 25